[Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
The data obtained during the past decade in experimental and clinical pharmacology show that the GABAergic drugs, with central activity, do not ameliorate the symptoms of the Parkinson's disease (PD), but would worsen the akineto-rigid syndrome, the dyskinesias and the deteriorating mental status in the later stages of the PD. On the other hand, recent data of experimental pharmacology suggest the possibility that glycinergic or glutamatergic derivatives, with central activity, would have a beneficial effect on the syndromes of the later stages of PD (declining efficacy of L-DOPA, dyskinesias, deteriorating mental status), which constitute, with the fluctuation of the response to L-DOPA, ("on-off" effects), the major problems of the PD's treatment. Some theoretical and experimental data also suggest the possibility of a beneficial effect of the glutamatergic drugs in the treatment of the "on-off" effects.
Vamvakidès
A
A
Laboratoire Chropi, Paris.
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D005971:Glutamates / Q000502:physiology*; D005998:Glycine / Q000502:physiology*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D000978:Antiparkinson Agents; D005971:Glutamates; D005680:gamma-Aminobutyric Acid; D005998:Glycine
Hypothèse de travail sur l'effet des dérivés GABAergiques, glycinergiques ou glutamatergiques dans le traitement de la maladie de Parkinson.